on ABIVAX (EPA:ABVX)
Abivax presents seven abstracts on Obefazimod at ECCO 2025
Biotech company Abivax has announced that it will present seven abstracts on Obefazimod at the 20th Annual Congress of the European Crohn's and Colitis Organization (ECCO). The scientific meeting will be held from February 19 to 22, 2025 in Berlin.
Obefazimod, an orally administered molecule, is in clinical development to treat moderately to severely active ulcerative colitis. Abstracts will include oral presentations and posters focusing on efficacy, tolerability and treatment-related quality of life. Speakers will include renowned specialists such as Prof. Silvio Danese and Prof. Séverine Vermeire.
The announcement marks a step in sharing Abivax's clinical advances with the international inflammatory bowel disease community.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news